Biomerica Secures $1.75M CDMO Deal for IVD Assay Development

Event summary

  • Biomerica lands a $1.75M Master Services Agreement with a confidential life sciences company for IVD assay development.
  • The three-year deal includes automatic one-year renewals and will be executed at Biomerica’s FDA-licensed, ISO 13485-certified facility in Irvine, California.
  • Revenue recognition is tied to milestone completions under multiple Statements of Work (SOWs).
  • The agreement leverages Biomerica’s 40-year expertise in ELISA-based assay development and regulatory compliance.

The big picture

Biomerica’s CDMO deal underscores the growing trend of diagnostic companies monetizing internal capabilities to diversify revenue streams. The $1.75M agreement highlights the strategic value of regulatory-approved infrastructure in a competitive IVD market. This move aligns with broader industry shifts toward capital-efficient, parallel revenue models in biotech.

What we're watching

Revenue Realization
Whether Biomerica can sustain momentum in its CDMO business while maintaining focus on its core inFoods® IBS product.
Operational Leverage
The pace at which Biomerica can scale its CDMO program with minimal incremental costs.
Market Differentiation
How Biomerica’s long-standing expertise in ELISA and regulatory compliance positions it against competitors in the CDMO space.

Related topics

Biotechnology Diagnostics